Hebei Changshan Biochem Pharma (300255) — Capital Reinvestment Ratio

Latest as of June 2025: 0.27x

Hebei Changshan Biochem Pharma (300255) has a Capital Reinvestment Ratio of 0.27x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥70.22 Million) in capital expenditures (CN¥18.63 Million). See cash generation quality of Hebei Changshan Biochem Pharma to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.27x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥70.22 Million
CNY

Capital Expenditures

CN¥18.63 Million
CNY

Data as of

Jun 2025
Most recent filing

Hebei Changshan Biochem Pharma Capital Reinvestment Ratio (2009–2024)

This chart tracks Hebei Changshan Biochem Pharma's Capital Reinvestment Ratio across 10 annual periods.

Annual Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma (2009–2024)

Year-by-year Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma from 2009 to 2024. For live market cap and broader valuation context, see 300255 company net worth.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 4.26x CN¥56.22 Million CN¥239.59 Million ▼ -39.9%
2023 7.10x CN¥33.73 Million CN¥239.32 Million ▼ -94.9%
2022 137.97x CN¥3.13 Million CN¥431.22 Million ▲ +28.6%
2021 107.29x CN¥2.87 Million CN¥308.08 Million ▲ +13277.0%
2018 0.80x CN¥292.81 Million CN¥234.85 Million ▼ -17.8%
2017 0.98x CN¥162.28 Million CN¥158.30 Million ▲ +73.8%
2016 0.56x CN¥171.96 Million CN¥96.52 Million ▼ -68.6%
2011 1.79x CN¥17.04 Million CN¥30.43 Million ▲ +39.0%
2010 1.28x CN¥29.25 Million CN¥37.56 Million ▲ +29.3%
2009 0.99x CN¥24.21 Million CN¥24.05 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow